2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159696D
    Cy3 labled ISIS 449884 sodium 98%
    Cy3 labled ISIS 449884 sodium is a Cy3 labled ISIS 449884 sodium.
    Cy3 labled ISIS 449884 sodium
  • HY-159796A
    Cefetecol 117211-03-7
    Ceftezole (GR69153) is a broad-spectrum cephalosporin antibiotic and an α-glucosidase inhibitor. Ceftezole inhibits bacterial cell lysis by inhibiting cell wall synthesis and binding to penicillin-binding proteins (PBPs). Ceftezole exhibits in vivo anti-diabetic activity in diabetic mice. Ceftezole can be used in antibacterial and anti-diabetic research.
    Cefetecol
  • HY-160169A
    Necrosis inhibitor 2 (hydrocholide) 98%
    Necrosis inhibitor 2 hydrocholide (Compound B19) is a cell necrosis inhibitor. Necrosis inhibitor 2 hydrocholide can be used to study diseases related to the necrosis pathway, including inflammation, tumors, metabolic diseases and neurodegenerative diseases.
    Necrosis inhibitor 2 (hydrocholide)
  • HY-163165S
    16:0-19:2-16:0 TG-d5 2342574-87-0 98%
    16:0-19:2-16:0 TG-d5 is the deuterium labeled triacylglycerols.
    16:0-19:2-16:0 TG-d5
  • HY-163253S
    HSD17B13-IN-56-d3 2770247-60-2 98%
    HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-56-d3
  • HY-163259S
    HSD17B13-IN-62-d3 2770247-67-9 98%
    HSD17B13-IN-62-d3 (176) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-62-d3
  • HY-163263S
    HSD17B13-IN-80-d3 2770247-70-4 98%
    HSD17B13-IN-80-d3 (179) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-80-d3
  • HY-16397AS
    Phenformin-d5 hydrochloride 98%
    Phenformin-d5 (Phenethylbiguanide-d5) hydrochloride is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an orally active biguanide hypoglycemic agent. Phenformin hydrochloride inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin hydrochloride inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.
    Phenformin-d5 hydrochloride
  • HY-164740B
    Plozasiran sodium scrambled negative control 98%
    Plozasiran sodium scrambled negative control is the sequence scrambled negative control of Plozasiran sodium.
    Plozasiran sodium scrambled negative control
  • HY-164740C
    FAM labled Plozasiran sodium 98%
    FAM labled Plozasiran sodiumis a FAM labled Plozasiran sodium.
    FAM labled Plozasiran sodium
  • HY-164740D
    Cy3 labled Plozasiran sodium 98%
    Cy3 labled Plozasiran sodium is a Cy3 labled Plozasiran sodium.
    Cy3 labled Plozasiran sodium
  • HY-166325A
    Ganglioside GD3-d3 ammonium 2692624-24-9 98%
    Ganglioside GD3-d3 ammonium is the deuterium labeled Ganglioside GD3 ammonium. Ganglioside GD3 ammonium is an ester product.
    Ganglioside GD3-d3 ammonium
  • HY-166501S
    1-Palmitoyl-2-stearoyl-3-chloropropanediol-d5
    1-Palmitoyl-2-stearoyl-3-chloropropanediol-d5 is the deuterium labeled 1-Palmitoyl-2-stearoyl-3-chloropropanediol (HY-165737). 1-Palmitoyl-2-stearoyl-3-chloropropanediol is an ester product.
    1-Palmitoyl-2-stearoyl-3-chloropropanediol-d5
  • HY-166652S
    Empagliflozin-d8 2714418-84-3
    Empagliflozin-d8 is the deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
    Empagliflozin-d8
  • HY-167814S
    Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt 98%
    Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt is the deuterium labeled Deferiprone O-β-D-glucuronide (HY-160078). Deferiprone O-β-D-glucuronide is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide shows the capability of reducing the iron burden in patients with β-thalassemia.
    Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt
  • HY-167906S
    Hexadecyl 2-((4-Nitrophenyl)thio)acetate-13C2
    Hexadecyl 2-((4-Nitrophenyl)thio)acetate-13C2 is the 13C-labeled Lunamarine (HY-167906). Lunamarine is a inhibitor of PDE5 with BBB permeability. Lunamarine can be used in the reseach of Pulmonary Arterial Hypertension (PAH) and Erectile Dysfunction (ED).
    Hexadecyl 2-((4-Nitrophenyl)thio)acetate-13C2
  • HY-16938S2
    5'-Methylthioadenosine-13C5 98%
    5'-Methylthioadenosine-13C5 (5'-(Methylthio)-5'-deoxyadenosine-13C5) is the 13C--labeled 5'-Methylthioadenosine (HY-16938). 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
    5'-Methylthioadenosine-13C5
  • HY-170273S
    4-((S)-2,3-Bis(palmitoyloxy)propoxy)-2-(trimethylammonio)butanoate-d9 2260669-85-8 98%
    4-((S)-2,3-Bis(palmitoyloxy)propoxy)-2-(trimethylammonio)butanoate-d9 is a glycerolipid.
    4-((S)-2,3-Bis(palmitoyloxy)propoxy)-2-(trimethylammonio)butanoate-d9
  • HY-172439S
    Simedeutirom 2403721-24-2 98%
    Simedeutirom is the agonist for thyroid hormone beta receptor (THRβ) and can be used for researchs of metabolic diseases, such as obesity and diabetes mellitus.
    Simedeutirom
  • HY-172883A
    (E/Z)-ABP/PPAR modulator 1
    (E/Z)-ABP/PPAR modulator 1 is a mixture of the E and Z isomers of ABP/PPAR modulator 1 (HY-172883). ABP/PPAR modulator 1 is an orally active FABP and PPAR multiple modulator (IC50s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC50 s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model.
    (E/Z)-ABP/PPAR modulator 1
Cat. No. Product Name / Synonyms Application Reactivity